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Abstract
This study reported the efficacy of short-course corticosteroids and convalescent plasma (CP) transfusion in treating five patients with severe COVID-19 disease. Five adults
(mean±standard deviation age: 70±9 years) with laboratoryconfirmed COVID-19 and severe hypoxemia (PaO2/FiO2
[P/F]<100) requiring invasive mechanical ventilation received
five days methylprednisolone (40 mg intravenously every 12

hours) and subsequent CP transfusion (250–400 ml). Compared with the baseline, P/F ratios increased by 46% and by
28% after short course corticosteroids and CP transfusion,
respectively. Four patients survived. Short-course corticosteroids and CP transfusion may improve hypoxemia in patients with severe COVID-19 disease.

Introduction

7] CP transfusion has preliminary promising results
against SARS-COV-2 in 2 case series.[8, 9] Clinical trials investigating the efficacy of CP are underway. This
study aimed to share our clinical experience with corticosteroids and CP transfusion in five critically ill patients with COVID-19.

COVID-19 is an enveloped single stranded RNA virus,
Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) that was first reported in Wuhan, China
in December 2019. Since then COVID-19 disease has
become a pandemic and spread to over 195 countries,
with millions of cases and thousands of deaths worldwide.[1] Several therapeutic agents were proposed,
including antiviral agents (e.g., lopinavir-ritonavir,
remdesivir), chloroquine/hydroxychloroquine, and
Interleukin-6 pathway inhibitors.[2] Currently, there is
a lack of definitive evidence of clinical benefits from
these therapeutic agents.
Corticosteroids were initially used in hospitalized patients with COVID-19 in China [3]; however, its use
remains controversial as it may delay viral clearance
and can cause complications.[4] Some experts advocate
low-dose corticosteroid use in certain circumstances
given the potential benefit of alleviating pulmonary
fibrosis.[5] Convalescent plasma (CP) transfusion is
another promising treatment for COVID-19 based on
prior experiences treating Ebola, Middle East respiratory syndrome coronavirus, SARS-CoV1 and H5N1.[6,
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Methods
This study was conducted by the Infectious Diseases Department at Christus Spohn Hospital, Corpus
Christi, Texas, USA, between March 23, 2020, and April
15, 2020. Food and Drug Administration (FDA) approval was obtained to use CP as an experimental therapy and as an emergency indication to treat severe
COVID-19 infection. Following FDA approval, the Institutional review board (IRB) approved the study, and
informed consent was obtained from the family to use
CP.
Patients were eligible for CP transfusion if they met the
following criteria: a) severe shortness of breath, respiratory rate > 30/mt, blood oxygen saturations <93%,
Lung infiltrates >50%, multi-organ failure along with
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confirmed COVID-19 diagnosis using the qualitative
reverse transcriptase-polymerase chain reaction (qRTPCR) (LabCorp Laboratory) on nasopharyngeal secretions; b) bilateral lung infiltrates requiring invasive mechanical ventilation; and c) PaO2/FiO2 (P/F) ratio less
than 100.
Plasma donors were selected if they were previously
diagnosed with laboratory-confirmed COVID-19 with
complete resolution of the symptoms for fourteen days
with negative result for COVID-19 on qRT-PCR. Appropriate type, screen, and cross-match were performed. Approximately 600 to 800 mL of convalescent
plasma was retrieved from each donor. The neutralizing activity of plasma against SARS-CoV-2 was not
evaluated in our laboratory. It is assumed that derived plasma has enough antibodies with neutralizing
activity. Following the donation, 250 to 400 ml of CP
was given to all patients at least once. In addition
to CP transfusion, these five patients received 5 days
short course of corticosteroids, defined as methylprednisolone 40 mg intravenously every 12 hours for five
days. Short course corticosteroids and plasma transfusion were given at different points of the patient’s
disease course. Data are presented as actual values or
mean (Standard deviations). Effect of short course corticosteroids and CP on P/F ratios and magnitude of
change in P/F ratios after the treatment of short course
corticosteroids and CP transfusion were summarized.
Data were analyzed using SPSS v.24 (IBM, Armonk,
NY).

Results
Five patients with severe COVID-19 infection who had
severe hypoxemia (PaO2/FiO2 [P/F]<100) requiring
invasive mechanical ventilation were admitted to ICU.
All were male and with a mean age of 70±9 years. All
the patients had one or more co-morbidities. Demographics, co-morbidities, and medical treatments administered during hospitalization are detailed in Table 1. All patients received short course methylprednisolone and CP transfusion. The volume of CP transfusion administered in our patients ranged from 250 ml
to 400 ml. In the first two patients (patients A and B),
CP transfusion was repeated three days after the initial
transfusion. CP was started after short course corticosteroids, except in Patient E where short course corticosteroids and CP transfusion were given same day. These
treatments and the starting day of the patient’s illness
are summarized in Table 1.
Methylprednisolone treatment preceded CP transfusion. The mean P/F ratio before short course corticosteroids was 82pm14 and increased to 161pm53, three
days after the treatment. Following CP transfusion, the
mean P/F ratio improved from 139pm54 to 175pm65.
The P/F ratios have increased by 46% and by 28%
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from finishing the treatment of short course corticosteroids and CP transfusions (Table 1). Trends of P/F
ratio changes of all patients are shown in Figure 1.
There were no significant side effects from methylprednisolone and CP transfusion during the hospital stay.
The mean duration of invasive mechanical ventilation
was 14 days (range: 4–22 days). Among these five patients, four survived and were successfully extubated
within 7 days of starting short course corticosteroids
and within five days after CP transfusion. One patient
with significant co-morbidities died due to multi-organ
failure from secondary infection.

Discussion
This case series delineated the clinical courses of five
patients with severe COVID-19 on mechanical ventilation requiring treatment of CP transfusion and short
course corticosteroid treatment. Improved oxygenation
indicated by the P/F ratio may be correlated with the
methylprednisolone and CP transfusion. In our study,
we have seen improvement in P/F ratios soon after
starting steroids. Patients that started on steroids and
CP transfusion earlier had a shorter ventilation course.
Improved P/F ratios after CP treatment seen in this
study was consistent with the results of two case-series
studies. Shen et al. demonstrated that CP transfusion
is associated with decreased viral loads and improvement in P/F ratios within 12 days in five patients. Unlike our study, they did not describe the timeline of
steroids vs COVID-19 plasma administration, which
could have skewed the results of oxygenation improvement, as the study did not differentiate between CP
and steroids.[8] Similarly, Duan et al. also demonstrated clinical improvement and significant decrease
in CRP level and viral loads and an increase in neutralizing antibody in ten patients.[9] The therapeutic effect
from CP transfusion against COVID-19 is pathophysiologically plausible. The convalescent plasma collected
from recovered patients from an infection contains antibodies that neutralizes the pathogen. Passive transfer of these antibodies from plasma transfusion is hypothesized to prevent infection or reduce the severity of current infection through several mechanisms,
including neutralization of infectivity via direct binding with pathogens, antibody-medicated complement
activation, and antibody-dependent cellular cytotoxicity.[6, 10]. These hypothetical effects were also observed in other infectious diseases (e.g. Ebola, SARSCoV).[6, 7] However, one should also note the potentially harmful effects associated with CP transfusion,
including transfusion-related infection (e.g. hepatitis C
virus) and transfusion-related reactions. The definitive
role of CP transfusion in the management of COVID-19
disease is evolving.
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Figure 1. The trend of changes of PaO2/FiO2 ratio after initiation of treatment of steroids and convalescent plasma transfusion.
A) Temporal changes in the P/F ratio of patients receiving steroids. Arrow represents the start date of treatment steroids. Patient A expired on
day 10 post the initiation of steroids; patient C was extubated on day 8 post the initiation of steroids; patient E was extubated on day 6 post the
initiation of steroids. Patient E does not have a baseline PaO2/FiO2 ratio before the initiation of treatment of steroids.
B) Temporal changes in the P/F ratio of patients receiving convalescent plasma transfusion. Arrow represents the start date of the convalescent
plasma (CP) transfusion. Patient A expired on day 10 post CP transfusion; patient B was extubated on day 8 post CP transfusion; patient C
was extubated on day 6 post CP transfusion; patient D was extubated on day 8 post CP transfusion; patient E was extubated on day 6 post CP
transfusion.
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Table 1. Demographics, clinical characteristics and administered treatment of the patients.

Patients
A

B

C

D

E

58
Male
119
37
No
HTN, DM, HIV

64
Male
105
31
No
HTN

77
Male
80
29
Ex-smoker
ESRD, DM, CHF

80
Male
109
33
No
HTN, CAD, CHF

72
Male
102
30
No
HTN, DM

Treatment
Mechanical Ventilation
Tocilizumab
Methylprednisolone
Plasma transfusion
Hydroxychloroquine with azithromycin
Vitamin C and Zinc

Day 2
Day 7
Day 9
Day 12
Day 2
Day 2

Day 5
Day 6
Day 13
Day 15
Day 2
Day 2

Day 1
None
Day 1
Day 3
Day 1
Day 1

Day 2
Day 8
Day 6
Day 13
Day 5
Day 5

Day 1
Day 1
Day 1
Day 1
Day 1
Day 1

PaO2/FiO2
Before steroids
After steroids
Percentage change after steroids (%)
Before CP
After CP
Percentage change after CP (%)
Survival

61
90
32
64
81
21
No

80
130
38
170
150
-13
Yes

90
180
50
180
190
5
Yes

100
180
44
180
200
10
Yes

80
228
65
100
256
61
Yes

Demographics
Age (years)
Gender
Weight (kg)
BMI
Smoker
Co-Morbidities

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; HTN, hypertension.

Corticosteroid use in COVID-19 infection remains controversial. Concerns for delayed viral clearance and increased risk for complications from high-dose corticosteroids have led to WHO and CDC recommendations
against its routine use in COVID-19. However, these
suggestions were based on observational studies with
potential selection bias and uncontrolled confounding that might obscure the clinical benefits of corticosteroids for a subset of patients with advanced acute
respiratory distress syndrome (ARDS), such as attenuation of pulmonary fibrosis.[5] The expert panel from
China recognized the potential benefits of short course
corticosteroids and advocates for its use in COVID-19
infections in certain settings.[7] The claimed benefits
of short course corticosteroids were observed in our
study. We observed a good response to short course
corticosteroids, with improved oxygenation and close
to 50% improvement in P/F ratio and a good survival
rate of 80% (4/5) among elderly patients with various
co-morbidities.
There were several limitations of this study. First, since
this was a small case series without controls, it prevented us from accurately ascertaining the definitive
therapeutic benefits of short course corticosteroids and
CP transfusion independently. Second, it was diffi-
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cult to differentiate the therapeutic effect of CP transfusion from the remaining effects of short course corticosteroids given prior. Furthermore, it was not feasible
to administer both a single agent and observe patients’
response before changing therapy in a critical setting.
Third, the lack of evidence in both decreasing viral
loads and increasing neutralizing antibody titers after
the short course corticosteroids and CP transfusion prevented us from confirming their efficacy. An additional
limitation was lead-time bias, as the observed therapeutic effects could have resulted from patients’ selfrecovery, as we have no controls for comparison. Furthermore, the time points of administered treatment
differ across patients, which could be another source of
heterogeneity. To understand better the timing for CP
transfusion and its benefits in COVID-19 patients, we
are planning a larger multicenter study with coordination of various centers in the USA.
In summary, short course corticosteroids and convalescent plasma transfusion may improve oxygenation
in patients with severe COVID-19 infections. Welldesigned studies with adequate statistical power will
shed more light on the benefits of short course corticosteroids and CP in patients with COVID-19 infections.
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